Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYT-510 in Healthy Subjects
NCT06670950Phase 1Completed
- Sponsor
- Synendos Therapeutics
- Start
- Nov 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SYT-510 (2 arms), sponsored by Synendos Therapeutics. Primary endpoints: Maximum Observed Concentration, Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration and 2 more. Started Nov 2024; status: completed.
02
Drugs
SYT-510
Beyond the preview
Go deeper on NCT06670950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06670950.